Further studies addressed to examining whether other mechanisms of NF-κB activation existing in diabetes such as advanced glycated end products (AGEs) or oxidative stress are involved in the lower risk of PCa observed in T2D are warranted. This evidence concerns the gene NFKB1 and type 2 diabetes mellitus.